Sermorelin and NAD+ are different substances. Sermorelin is a peptide involved in growth hormone-releasing signaling. NAD+ is a coenzyme involved in cellular metabolism. Their frequent appearance on the same wellness menu does not make them competing versions of one treatment.

Claims about energy and healthy aging can make the comparison sound simple. The useful question is what condition or symptom is being addressed, what exact product and route are proposed, and what human evidence supports that use.

The considered take

A shared wellness label is not shared evidence. Evaluate each treatment and any proposed combination separately.

Biology explains interest, not a guaranteed benefit

A molecule's role in normal physiology does not establish that giving more of it improves health. The same principle applies to a growth hormone signal and a metabolic coenzyme. A mechanism is a rationale for research, not the result of a clinical trial.

For either product, look for evidence that matches the preparation, route, population, and desired outcome. A biomarker change is not automatically improved energy or longer life. The sermorelin evidence guide describes the questions to apply.

Sources: Endotext: Growth Hormone and Aging · Grant et al.: NAD+ infusion metabolome pilot study

NAD+ routes and related ingredients are not interchangeable

An intravenous NAD+ infusion, a subcutaneous preparation, a nasal product, and an oral precursor involve different delivery and evidence questions. Research on one cannot simply establish another's clinical effect. A small study of metabolism during an infusion is not an anti-aging outcomes trial.

The same caution applies to sermorelin tablets and injections. If a provider cites a paper, identify what participants actually received before drawing conclusions about the offered product. Tablets versus injections gives a concrete example of why route matters.

Sources: Grant et al.: NAD+ infusion metabolome pilot study · FDA: Risks of compounded drugs

Compounded injectable products need quality scrutiny

FDA has warned compounders about using ingredients suitable for sterile compounding, including concerns involving food-grade NAD+ used in intravenous products. The agency has received adverse-event reports consistent with excessive endotoxin exposure in this context.

That warning does not establish that every NAD+ product has the same defect. It does show why an ingredient's presence in food or the body is not proof of suitability for injection. Verify the pharmacy and actual formulation using the pharmacy-check guide.

Sources: FDA: Ingredients suitable for sterile compounding

A combined program needs a reason for both items

Do not assume that different mechanisms mean additive benefit or established compatibility. Ask why each prescription is included, what evidence supports their combined use, and how the clinician would assess a symptom after both are started.

Compare the full cost, visits, laboratory work, and practical burden. If the goal is unexplained fatigue, the evaluation may identify another cause and treatment. The consultation checklist and worth-it guide help keep the decision anchored to an actual need.

Sources: MedlinePlus: Fatigue · FDA: Compounding questions and answers

Sources behind this article

Provider pages describe their own services. They are not independent proof of health outcomes. Pricing and availability can change.

  1. Endotext: Growth Hormone and AgingExpert clinical evidence review · Separates hormone and body-composition findings from functional outcomes and long-term unknowns.
  2. Grant et al.: NAD+ infusion metabolome pilot studyPrimary or authoritative reference · Small IV metabolism study; not proof of anti-aging outcomes or another route.
  3. FDA: Risks of compounded drugsUS regulator · Explains lack of FDA approval and the risks of poor-quality compounded preparations.
  4. FDA: Ingredients suitable for sterile compoundingPrimary or authoritative reference · NAD+ quality warning; not a claim that every product is contaminated.
  5. MedlinePlus: FatigueUS National Library of Medicine · Fatigue has many causes that may need evaluation.
  6. FDA: Compounding questions and answersUS regulator · Compounded medicines differ from FDA-approved generic drugs.